KEYTRUDA QLEX

Merck Sharp & Dohme LLC🇺🇸 United States

FDA Page

Effective Date: Jul 31, 2026
Approval ID: 097d166f-b73b-41d3-9b37-7653cd2a0c41
Products: 2 registered
Version: 18

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use KEYTRUDA QLEX safely and effectively. See full prescribing information for KEYTRUDA QLEX. KEYTRUDA QLEX(pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use Initial U.S. Approval: 2025

Quick Stats

Total Products2

Labelers2

Label Sections34

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.